On May 19, 2022 Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, reported that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022 (Press release, Theseus Pharmaceuticals, MAY 19, 2022, View Source [SID1234614898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Event: H.C. Wainwright Global Investment Conference
Date / Time: Monday, May 23rd – Thursday, May 26th, 2022, on demand
Format: Virtual Presentation

Event: Jefferies Healthcare Conference
Date / Time: Thursday, June 9th, 2022, at 4:30pm ET
Format: Live Fireside Chat

A live webcast will be available in the Events section of the company’s investor relations website at ir.theseusrx.com and archived for 30 days following the presentations.

Management will also be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Theseus management team should contact their H.C. Wainwright or Jefferies representatives.

On May 19, 2022 Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported that the Company will participate in the following upcoming investors’ conferences (Press release, Ryvu Therapeutics, MAY 19, 2022, View Source [SID1234614897]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Global Healthcare Conference
Format: Corporate overview presentation and one-on-one investor meetings
Date: Monday, May 23rd, 2022, in New York, NY
Presentation Time: 11:30 AM EST

H.C. Wainwright Global Investment Conference
Format: Corporate overview presentation and one-on-one investor meetings
Date: Wednesday, May 25th, 2022, in Miami, FL
Presentation Time: 4:30 PM EST

Erste CEE Technology & Innovation Conference
Format: One-on-one, and group investor meetings
Date: Wednesday, May 25th, 2022, Virtual

IPOPEMA CEE Days
Format: Group investor meeting and Q&A session
Date: Wednesday, June 1st, 2022, Warsaw, Poland
Meeting Time: 2 PM CEST

Pekao Technology Conference
Format: One-on-one investor meetings
Date: Wednesday, June 8th, 2022, Virtual

During the UBS 2022 Global Healthcare Conference and the 2022 H.C. Wainwright Global Investment Conferences, Vatnak Vat-Ho, Chief Business Officer of Ryvu Therapeutics will give a corporate overview and participate in investor meetings. The presentations will be available to conference registrants on-demand. Broader Ryvu management team will be available for meetings during Erste, Ipopema, and Pekao conferences.

On May 19, 2022 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, reported that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 (Press release, Medtronic, MAY 19, 2022, View Source [SID1234614896]). A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at View Source The news release will include summary financial information for the company’s fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday, May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at View Source

Within 24 hours of the broadcast, a replay and transcript of the prepared remarks will be available by clicking on the Investor Events link at View Source

Looking ahead, Medtronic plans to report its fiscal year 2023 first, second, third, and fourth quarter results on Tuesday, August 23, 2022, November 22, 2022, February 21, 2023, and Thursday, May 25, 2023, respectively. For these events, confirmation and additional details will be provided closer to the specific event.

On May 19, 2022 Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, reported that two abstracts were selected for presentation as posters at the 25th Annual American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Meeting on May 17 and 18, 2022 (Press release, Avenge Bio, MAY 19, 2022, View Source;cell-therapy-asgct-annual-meeting-301551364.html [SID1234614895]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present additional preclinical data that support our lead development program, AVB-001, as we advance towards filing an IND in Q2 2022 and a Phase 1 clinical trial in ovarian cancer in 2H 2022," said Douglas Carlson, Chief Operating and Financial Officer. "In addition, we continue to build a robust data set for AVB-001, a novel immunotherapy, in malignant pleural mesothelioma. All of our development programs leverage Avenge’s LOCOcyte platform to deliver proprietary encapsulated engineered human cells to the local tumor environment."

Details on Avenge’s presentations at ASGTC are as follows:

Poster Title: Tumor Adjacent IL-2 Cytokine Factories for Eradication of Various Solid Tumor in Mice Through Cytotoxic T-cell Activation with Safe and Predictable Dosing in Non-human Primates.
Abstract #: 657
Date and Time: May 17, 2022, 5:30pm-6:30pm ET

Poster Title: Evaluation of Implantable Cytokine Factories in Combination with Checkpoint Inhibitors for Eradication of Malignant Pleural Mesothelioma (MPM) Tumors in Mice.
Abstract #: 1097
Date and Time: May 18, 2022, 5:30pm-6:30pm ET

The posters will be available on the Presentations and Publications section of www.avengebio.com following the conference.

On May 19, 2022 Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, reported that it will be presenting details on the trial design for the INBRX-109 Phase 2 potentially registration-enabling trial in conventional chondrosarcoma at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Annual Meeting to be held June 3rd through June 7th, 2022 in Chicago, Illinois (Press release, Inhibrx, MAY 19, 2022, View Source [SID1234614894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentation are shared below:

Title: A randomized, placebo-controlled phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma
Track/Session: Sarcoma
Poster number:486a
Presenter: Sant P. Chawla, MD
Date & Time: Sunday, June 5, 2022 from 9 a.m. to 11 a.m. CST
Location: Exhibit Hall A

The poster will be available on-demand on the ASCO (Free ASCO Whitepaper) website for attendees beginning at 9:00 AM CST on Friday, June 3, 2022. Upon release at ASCO (Free ASCO Whitepaper), the scientific poster will be accessible through Inhibrx’s website at View Source

About Chondrosarcoma

Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the United States and the European Union. There are currently no systemic therapies approved for the treatment of chondrosarcoma.

About INBRX-109

INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 signaling.

In January 2021, the FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. Further, in December 2021, FDA granted Orphan Drug Designation to INBRX-109 for this indication.

In November 2021, Inhibrx provided updated results from its ongoing Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with conventional chondrosarcoma. Preliminary disease control was observed in 16 of the 18 evaluable patients (89%) measured by RECISTv1.1, with two of the 18 achieving partial responses (11%). Based on preliminary results of the ongoing Phase 1 trial, the median progression-free survival (PFS) is 7.4 months, and the median overall survival has not been reached. Three patients have exceeded 61 weeks on treatment with INBRX-109, with 77 weeks being the longest duration of stable disease observed to date.

In June 2021, Inhibrx initiated a randomized, blinded, placebo-controlled, potentially registration-enabling Phase 2 trial of INBRX-109 in conventional chondrosarcoma. The trial will be conducted at approximately 51 sites within eight countries, with 30 of those sites in the United States.